- 期刊
Imatinib Mesylate Therapy in Advanced Gastrointestinal Stromal Tumors: Experience from a Single Institute
Imatinib Mesylate 對於晚期基質細胞腫瘤的治療：單一機構之經驗
摘要
胃腸道基質細胞腫瘤是一種由胃腸道及腹腔之間質組織而來的罕見的軟組織肉瘤。因爲對於晚期之病患無有效之治療方法，其預後一般均不佳。近來由於選擇性的tyrosine激脢抑制藥物，imatinib mesylate，顯示對基質細胞腫瘤有不錯的療效，因此提出我們對於晚期基質細胞腫瘤的病患使用imatinib治療的經驗。一共有十四位病患：包括十名男性及四名女性，其中位數年齡爲五十一歲。小腸是最常見的原發部位，而肝臟是最常見的轉移部位。大多數的病患在治療中均有可忍受的副作用括水腫(眼週圍或下肢水腫)及腹痛。病患有不錯的累積存活率，只有兩位病患在治療中死亡。病患對於imatinib治療有不錯的療效：包括一位病患達到完全反應；七位是穩定疾病及三位部份反應。這結果顯示imatinib對於晚期之胃腸道基質細胞腫瘤有很好的療效。
並列摘要
Gastrointestinal stromal tumors (GIST) are rare soft tissue sarcomas arising primarily from mesenchymal tissue in the gastrointestinal tract and abdomen. Since there is no effective treatment in the advanced stages, the outcome is poor in such patients. Recently, imatinib mesylate, a selective tyrosine kinase inhibitor, has shown a promising effect in GIST. Hence, we report our experience on the management of advanced GIST with imatinib therapy. A total of 14 patients were enrolled in this study, including 10 males and four females (median age, 51 years). The results showed that the small intestine was the most frequent site of primary lesion, while the liver was the most frequently metastasized organ. Most of the patients experienced tolerable side effects with imatinib therapy, including edema of periorbital area and/or legs and abdominal pain. Only two mortalities were noted during follow-up. The patients clinically benefited from imatinib therapy, with one patient having a complete response, three having a partial response, and seven having stable disease. The results demonstrate promising effects of imatinib in advanced GIST.